

## **SECOND ADDENDUM TO HPRA POLICY ON THE SUPPLY OF ANTIPARASITIC VETERINARY MEDICINAL PRODUCTS FOR COMPANION ANIMALS**

August 2022

On 23 March 2022, the Authority of the HPRA, having received the advice of the HPRA's Advisory Committee for Veterinary Medicines (ACVM), accepted that an application for a topical spot-on adulticidal flea and tick product containing fipronil and s-methoprene and which does not bear an indication for 'flea allergic dermatitis' (FAD), could in principle be supplied under the category 'Companion Animal Medicine' (CAM supply category). The ACVM met on 2 March 2022 to consider the position on foot of an application from a marketing authorisation holder. Formerly, such products were supplied under the 'Licensed Merchant' (LM) category.

The effect of this policy change means that in future spot-on products for companion animals which contain fipronil, or fipronil and s-methoprene, or other active substances that have well recognised efficacy and an exemplary safety profile (over more than five years) and which also do not carry an FAD claim, may similarly be considered for supply under CAM classification, on submission of a variation application to, and upon approval by, the HPRA.

ENDS